Tetra Therapeutics Reports Positive Results of BPN14770 in P-II Study for Fragile X Syndrome

November 3, 2020 Auto Bot Clinical Trials, P-II, patients, Positive, reports, results, Study 0

Shots:

  • The P-II study is a two-way crossover study assessing BPN14770 (25mg, bid) vs PBO in 30 adult male patients aged 18-45yrs. with FXS due to >200 CGG repeats in the FMR1 gene
  • The study demonstrated benefits in oral reading recognition (+2.80), picture vocabulary (+5.79), cognition crystallized composite score (+5.29), benefits were maintained up to 12wks. and was well tolerated
  • BPN14770 is a novel therapy that selectively inhibits PDE4D to increase the levels of cAMP. In preclinical trials, it promotes the maturation of connections between neurons, which is impaired in patients with FXS and has received the US FDA’s ODD as well as approved for investigational use in the US

Click here to­ read the full press release/ article | Ref: Businesswire | Image: Tetra Therapeutics

The post Tetra Therapeutics Reports Positive Results of BPN14770 in P-II Study for Fragile X Syndrome first appeared on PharmaShots.